Ahmar U Zaidi
Overview
Explore the profile of Ahmar U Zaidi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
114
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Idowu M, Otieno L, Dumitriu B, Lobo C, Thein S, Andemariam B, et al.
Lancet Haematol
. 2024 Dec;
12(1):e35-e44.
PMID: 39644907
Background: Sickle cell disease, a debilitating, inherited haemolytic anaemia with premature morbidity and mortality, affects millions globally. Mitapivat, a first-in-class, oral, allosteric activator of pyruvate kinase, improves red blood cell...
2.
Glaros A, Callaghan M, Smith W, Zaidi A
EJHaem
. 2022 Sep;
3(3):653-659.
PMID: 36051054
Evidence suggests neuropathic pain (NP) develops over time in sickle cell disease (SCD), contributing to a complex, difficult-to-treat phenotype, with management based on scant evidence. One characteristic of NP found...
3.
Seddiq M, Zaidi A, Powell W, Henry M
J Pediatr Hematol Oncol
. 2022 Jan;
44(3):106-108.
PMID: 35082242
Primary cardiac tumors are quite rare in children, and only a small portion are malignant. Presenting symptoms may be nonspecific, often mimicking those of congestive heart failure, pulmonary embolism, and...
4.
Zaidi A, Glaros A, Lee S, Wang T, Bhojwani R, Morris E, et al.
Orphanet J Rare Dis
. 2021 Nov;
16(1):460.
PMID: 34727959
Background And Purpose: Sickle cell disease (SCD) is a collection of rare inherited blood disorders affecting approximately 100,000 people in the U.S. and 20-25 million people globally. Individuals with SCD...
5.
Zaidi A, Estepp J, Shah N, Alkindi S, Ezzat H, Lam H, et al.
Contemp Clin Trials
. 2021 Sep;
110:106546.
PMID: 34509600
The pivotal Endari trial in sickle cell disease showed a reduction in pain crises events. This reanalysis of the l-glutamine phase 3 trial using annual rates of pain crises, consistent...
6.
Hines P, Callaghan M, Zaidi A, Gao X, Liu K, White J, et al.
Br J Haematol
. 2021 Sep;
194(6):1074-1082.
PMID: 34472086
Blood cell adhesion to P-selectin and vascular cell adhesion molecule-1 (VCAM-1) contributes to the pathophysiology of vaso-occlusion crisis (VOC) events in individuals with sickle cell disease (SCD). We evaluated the...
7.
8.
Glaros A, Razvi R, Shah N, Zaidi A
Ther Adv Hematol
. 2021 Apr;
12:20406207211001136.
PMID: 33796238
Sickle cell disease, despite its recognition as a severely debilitating genetic condition affecting hundreds of thousands of neonates throughout the world each year, was not a target of pharmaceutical research...
9.
Zaidi A, Glaros A, Weyand A
Blood Adv
. 2021 Feb;
5(1):277-278.
PMID: 33570648
No abstract available.
10.
Minniti C, Zaidi A, Nouraie M, Manwani D, Crouch G, Crouch A, et al.
Blood Adv
. 2021 Feb;
5(1):207-215.
PMID: 33570644
We aimed to identify predictors of outcomes and survival in patients living in 4 major metropolitan areas who had sickle cell disease (SCD) and COVID-19 to inform best approaches to...